Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: To assess the characteristics of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and investigated whether all KRAS mutations predict poor prognosis in patients with unresectable colorectal liver metastasis (CRLM). Methods: Correlations between KRAS-mutation status and clinicopathological characteristics of 93 patients with unresectable CRLM at our institution between 2010 and 2018 were retrospectively analyzed. Kaplan–Meier and Cox proportional hazard models were used to evaluate the prognostic significance of KRAS mutations. Results: KRAS were primarily single-point mutations, identified in 41.9% of patients. There were no significant differences in clinicopathological characteristics between wild-type KRAS and mutant KRAS. Patients with mutant KRAS had significantly worse overall survival (OS) and progression-free survival (PFS) than those with wild-type KRAS. Moreover, patients with codon 12 mutations had worse OS and PFS than those with wild-type KRAS, whereas mutations in codon 13 were not associated with a worse prognosis. Among the 5 most common mutations in codons 12, G12V, and G12D were associated with worse OS, furthermore, G12C mutation seemed to associated with worse PFS than patients with wild-type KRAS. Conclusion: KRAS codon 12 mutations were predictive for a poor prognosis in patients with unresectable CRLM. G12D and G12V mutations were associated with worse OS, whereas G12C mutation seemed to be associated with decreased PFS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, 4 recent studies from Japan, US, and China reported poorer survival rates and significantly inferior PFS in patients with KRAS G12C than in those with other KRASm.69,78-80”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Research works printed but not linked: 31
- 10.1007/s10434-000-0643-3 · DOI · Paper page
- 10.1002/bjs.7527 · doi:10.1002/bjs.7527
- 10.1590/S0100-879X2010007500103 · DOI
- 10.1001/jamasurg.2015.0313 · DOI · Paper page
- 10.1002/cncr.30085 · DOI
- 10.1097/SLA.0b013e3182a5025a · DOI · Paper page
- 10.1002/cncr.30351 · DOI
- 10.1245/s10434-016-5361-6 · DOI
- 10.6004/jadpro.2015.6.5.7 · DOI
- 10.1245/s10434-015-4587-z · DOI
- 10.1007/s11605-016-3198-8 · DOI
- 10.1158/1078-0432.CCR-11-3210 · DOI · Paper page
- 10.1245/s10434-016-5299-8 · doi:10.1245/s10434-016-5299-8
- 10.1001/jamasurg.2013.1 · doi:10.1001/jamasurg.2013.1
- 10.1007/s00384-015-2228-4 · DOI
- 10.1111/j.1463-1318.2011.02817.x · DOI
- 10.1007/s00384-008-0456-6 · DOI
- 10.1093/annonc/mdm496 · DOI · Paper page
- 10.1016/0016-5085(93)90835-Z · DOI · Paper page
- 10.1056/NEJM198809013190901 · DOI · Paper page
- 10.1007/BF00690419 · DOI · Paper page
- 10.1038/327293a0 · DOI · Paper page
- 10.1016/0960-7404(92)90088-3 · DOI
- 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N · DOI · Paper page
- 10.1038/nm.3511 · DOI · Paper page
- Guerrero S, 2000, Cancer Res., 60, 6750
- 10.18632/oncotarget.13697 · DOI
- 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E · DOI · Paper page
- 10.1093/jnci/djr523 · DOI · Paper page
- 10.1093/carcin/bgi190 · DOI
- 10.1016/j.taap.2008.04.014 · DOI
Cited by
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Metadata
- Authors
- Lin, Z., Liu, Y., Cai, S., Yang, C., Zhou, L., & Li, W.
- Affiliations
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China
- National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
- Fujian Provincial Hospital, Fuzhou, China
- ORCID
- Li, Weihua
- Venue
- Technology in Cancer Research & Treatment
- Publisher
- SAGE Publications
- Published
- 2021-01
- Volume
- 20
- ISSN
- 1533-0346
- 1533-0338
- Cited by
- 1
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. https://app.cochat.ai/papers/10.1177/15330338211039131
- The paper
- Lin, Z., Liu, Y., Cai, S., Yang, C., Zhou, L., & Li, W. (2021). Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338211039131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.